Merck partners with Habitat for Humanity in asthma awareness effort

Share this article:
Merck partners with Habitat for Humanity in asthma awareness effort
Merck partners with Habitat for Humanity in asthma awareness effort
Merck is launching Build Smart, Breathe Easier, an asthma awareness campaign starring celebrity carpenter Carter Oosterhouse, who will build four homes with asthma-healthy features.

Oosterhouse, a fixture on HGTV, will build houses with low-income families that suffer from asthma in Atlanta, Detroit, LA and Philadelphia as part of the campaign, for which Merck is partnering with Habitat for Humanity and the Asthma and Allergy Foundation of America (AAFA). The campaign will emphasize the use of easy-to-clean, irritant-free materials, such as non-toxic paint and hard-surface floors, as a means of limiting asthma flare-ups, and will raise awareness of household asthma triggers such as dust mites, mold, pet dander and strong fumes and ways to control them.

Merck and AAFA employees will volunteer their labor on the homes, working alongside Oosterhouse and four families selected by Habitat for Humanity on homes built according to the principles of AAFA's Asthma and Allergy Friendly Certification Program.  

"Our goal is to educate about how to take steps to try to reduce triggers in the home," said Oosterhouse on the campaign's Facebook page, "and to encourage people with asthma to speak with their doctor about the appropriate treatment approach for their individual needs."

The campaign's Facebook page, though bereft of branding, does link to Merck-branded “asthma tracking tool (MerckEngage),” “self-management action plan” and “therapy assessment questionnaire.”

Merck's respiratory portfolio includes Asmanex, Dulera, Foradil, Proventil and Singulair for asthma as well as Clarinex and Nasonex for allergies.
Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.